Prosecution Insights
Last updated: November 08, 2026
Application No. 18/683,925

EMBRYONIC NUCLEIC ACID ANALYSIS

Final Rejection §103
Filed
Feb 15, 2024
Priority
Aug 16, 2021 — provisional 63/233,662 +1 more
Examiner
SALMON, KATHERINE D
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bioskryb Genomics Inc.
OA Round
2 (Final)
43%
Grant Probability
Moderate
3-4
OA Rounds
1y 3m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allowance Rate
342 granted / 799 resolved
-17.2% vs TC avg
Strong +38% interview lift
Without
With
+37.9%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
71 currently pending
Career history
920
Total Applications
across all art units

Statute-Specific Performance

§101
19.5%
-20.5% vs TC avg
§103
28.2%
-11.8% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
35.2%
-4.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 799 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is in response to papers filed 7/21/2026. Claims 1-2, 5-7, 11, 15-16, 30, 32, 34, 38-39, 46, 49, 57, 59-62 are pending. Claims 3-4, 8-10, 12-14, 17 29, 31, 33, 35-37, 40-45, 47-48, 50-56, and 58 have been cancelled. The following rejections are modified as necessitated by amendment with response to arguments following. This action is FINAL. Withdrawn Objections and Rejections The objection to the claims made in the previous office action is withdrawn based upon amendments to the claims. The 35 USC 112b rejection made in the previous office action is withdrawn based upon amendments to the claims and cancellation of claims. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1,2,5,6,7,11,15,16,30,32,34,46,49,57, 59-62 is/are rejected under 35 U.S.C. 103 as being unpatentable over Konstantinidis et al (RBMO April 2020 Vol 40 p. 479-493) in view of Jasper et al. (WO 2020/077400 April 23, 2020). With regard to claim 1, Konstantinidis et al teaches isolating nucleic acids from an embryonic cell (p. 480 last paragraph). Konstantinidis et al teaches detection of SNP analysis using nucleic acid isolated (p. 481). Konstantinidis et al teaches copy number variation and single nucleic variation (p. 481-482). However, Konstantinidis does not teach use of terminated nucleic acid replication (e.g. LAMP) and sequencing. With regard to claim 2, Konstantinidis et al teaches trophectoderm cells (p. 480 last paragraphs). With regard to claims 5, Konstantinidis et al teaches aneuploidy analysis (p. 481). With regard to claim 7, Konstantinidis et al teaches detection of trisomy 21 (p. 483 middle column). With regard to claim 15, Konstantinidis et al teaches detection of cell from a 5-day old blastocyte (p. 483 1st column last parpaghra). With regard to claim 16, Konstantinidis et al teaches 3 to 10 cells were used (p. 480 last parpaghra). With regard to claim 34, Konstantinidis et al teaches trophectoderm cells (p. 480 last paragraphs). With regard to claim 46, Konstantinidis et al. teaches isolating cells from a pregnant woman within early states (less than 5 weeks) (p. 488 middle column). With regard to claim 57, and 60-62, Konstantinidis et al. teaches obtaining isolating nucleic acids from an embryonic cell (p. 480 last paragraph). Konstantinidis et al teaches detection of SNP analysis using nucleic acid isolated (p. 481). Konstantinidis et al teaches determining copy number variation and single nucleic variation (p. 481-482). Konstantinidis et al teaches 3 to 10 cells were used (p. 480 last parpaghra). However, Konstantinidis does not teach use of terminated nucleic acid replication (e.g. LAMP). However, Konstantinidis et al does not teach PGT testing or specific methods of detection of primers and sequencing. With regard to claim 1, although Konstantinidis et al. does not teach the particular workflow for detecting of abnormalities in the sample, Jasper et al. teaches using primer, polymerase, and the use of LAMP assay and sequencing (para 9, 14, and 68-76). LAMP assay involves the use of a termination nucleotide (para 68). With regard to claim 6, Jasper et al teaches that sequencing was used to determine nucleic acids in embryo cells (p. 5). Jasper et al. teaches that the first step before sequencing is to prepare the cells using PGT-A (para 5). With regard to claim 11, Jasper et al. teaches that one can screen deletion, duplication (para 37) that would include whole duplication of a chromosome. With regard to claims 30, Jasper et al. teaches whole genome sequencing that can include all exons (para 5 and 60). With regard to claim 32, and 57 although Konstantinidis et al. does not teach the particular workflow for detecting of abnormalities in the sample, Jasper et al. teaches using primer, polymerase, and the use of LAMP assay (para 9, 14, and 68-76). LAMP assay involves the use of a termination nucleotide (para 68). With regard to claim 49, and 59, Konstantinidis et al. teaches that the termination is a locked nucleic acid (para 68-76). Therefore it would be prima facie obvious to one of ordinary skill in the art at the time of the effective filing date to modify the method of Konstantinidis et al. to use known methods of detecting variants in an embryonic cell sample including the method of Jasper et al. The ordinary artisan would be motivated to use the methods of Jasper et al as Jasper et al taches sequencing and LAMP assays that are known methods of detecting variants. Further Jasper et al teaches that this methodology can be used to detect embryonic cells. Response to Arguments The reply traverses the rejection. A summary of the arguments is provided below with response to arguments following. The reply asserts that Konstantinidis does not provide the steps of terminator (p. 9). The reply asserts that Jasper only describes the use of a reversible terminator-based sequencing in the context of NGS and not strand displacement (p. 10). These arguments have been reviewed but have not been found persuasive. Although Jasper et al. does teach NGS (which would encompass sequencing), the combination of Konstantinidis et al. and Jasper suggests the combination of steps that includes LAMP, which encompasses terminators in strand displacement. As such the combination of claims encompass the required steps of the claim. Claim(s) 38-39 is/are rejected under 35 U.S.C. 103 as being unpatentable over Konstantinidis et al (RBMO April 2020 Vol 40 p. 479-493) and Jasper et al. (WO 2020/077400 April 23, 2020) as applied to claims 6,11,28,30,31,32,34,46,49,57, 59-62 in view of Becherer et al. (Anal Methods Jan 2020 Vol 12 p. 717). Konstantinidis et al teaches isolating nucleic acids from an embryonic cell (p. 480 last paragraph). Konstantinidis et al teaches detection of SNP analysis using nucleic acid isolated (p. 481). As such Konstantinidis et al teaches a sample workflow. Konstantinidis et al teaches determining copy number variation and single nucleic variation (p. 481-482). Jasper et al. teaches using primer, polymerase, and the use of LAMP assay (para 9, 14, and 68-76). LAMP assay involves the use of a termination nucleotide (para 68). However, Konstantinidis et al and Jasper et al do not teach labeling with an antibody. With regard to claims 38-39, Becherer et al. teaches LAMP assays for sequence specific detection (abstract). Becherer et al. teaches the use of antibody attached for LAMP assay (p. 730). Therefore it would be prima facie to one of ordinary skill in the art at the time of the effective filing date to use one of the finite known labeling methods for LAMP assays as taught by Becherer et al. The ordinary artisan would have a reasonable expectation of success as Becherer et al teaches use of the label for sequence specific detection. Response to Arguments The reply traverses the rejection. A summary of the arguments is provided below with response to arguments following. The reply does not provide any other arguments other than what is addressed above (p. 10). Conclusion No claims are allowed, Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE D SALMON whose telephone number is (571)272-3316. The examiner can normally be reached 9-530. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Cheng (Winston) Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE D SALMON/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Feb 15, 2024
Application Filed
Apr 21, 2026
Non-Final Rejection mailed — §103
Jul 21, 2026
Response Filed
Oct 05, 2026
Final Rejection mailed — §103
Nov 04, 2026
Applicant Interview (Telephonic)
Nov 04, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767985
METHODS OF DIAGNOSING A DISEASE STATE
5y 4m to grant Granted Oct 20, 2026
Patent 12760366
METHODS FOR DETERMINING RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR THERAPY IN THE TREATMENT OF PSORIASIS
4y 6m to grant Granted Oct 13, 2026
Patent 12748103
METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS
3y 9m to grant Granted Sep 29, 2026
Patent 12729405
METHOD AND KIT FOR DETERMINING BENEFIT OF CHEMOTHERAPY
4y 6m to grant Granted Sep 08, 2026
Patent 12709776
NOVEL MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION IN PANCREATIC CANCER
4y 12m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
43%
Grant Probability
81%
With Interview (+37.9%)
4y 0m (~1y 3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 799 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month